Combination of Targeting Gene-ViroTherapy with 5-FU enhances antitumor efficacy in malignant colorectal carcinoma

Journal of Interferon and Cytokine Research

Volumn 24, Issue 4, 2004, Pages 219-230

  Qiu, Songbo ^a,b   Ruan, Hongmei ^a   Pei, Zifei ^b   Hu, Baoli ^a   Lan, Ping ^a   Wang, Jinhui ^b   Zhang, Zilai ^b   Gu, Jinfa ^b   Sun, Lanying ^b   Qian, Cheng ^c   Liu, Xinyuan ^b   Qi, Yipeng ^a  

^a WUHAN UNIVERSITY   (China)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BUFFER; ENZYME; FLUOROURACIL; ONYX 015; PHOSPHATE; SODIUM CHLORIDE;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CANCER TISSUE; CARCINOMA CELL; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOLYSIS; DEATH; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME BLOOD LEVEL; EXPERIMENT; GENE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HTRAIL GENE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER TOXICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL; TUMOR VOLUME; TUMOR XENOGRAFT; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS REGULATORY PROTEINS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; COLORECTAL NEOPLASMS; DRUG SYNERGISM; FLUOROURACIL; GENE THERAPY; GENETIC VECTORS; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MICE, NUDE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; ANIMALIA;

EID: 11144354510     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/107999004323034097     Document Type: Article

References (35)

1. BARKER, D.D., and BERK, A.J. (1987). Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156, 107-121.
2. BISCHOFF, J.R., KIRN, D.H., WILLIAMS, A., HEISE, C., HORN, S., MUNA, M., NG, L., NYE, J.A., SAMPSON-JOHANNES, A., FATTAEY, A., and McCORMICK, F. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376.
3. HEISE, C., SAMPSON-JOHANNES, A., WILLIAMS, A., McCORMICK, F., VON HOFF, D.D., and KRIN, D.H. (1997). ONYX015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3, 639-645.
4. HEISE, C.C., WILLIAMS, A.M., XUE, S., PROPST, M., and KIRN, D.H. (1999). Intravenous administration of ONYX015, a selectively replicating adenovirus, induces antitumor efficacy. Cancer Res. 59, 2623-2628.
5. ROGULSKI, K.R., FREYTAG, S.O., ZHANG, K., GILBERT, J.D., PAIELLI, D.L., KIM, J.H., HEISE, C.C., and KIRN, D.H. (2000). In vivo antitumor activity of ONYX015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res. 60, 1193-1196.
6. VASEY, P., SHULMAN, L., GORE, M., KIRN, D., and KAYE. S. (2000). Phase I trial of intraperitoneal ONYX015 adenovirus in patients with recurrent ovarian carcioma. Proc. Am. Soc. Clin. Oncol. 19, 1512.
7. KHURI, F.R., NEMUNAITIS, J., GANLY, I., ARSENEAU, J., TANNOCK, I.F., ROMEL, L., GORE, M., IRONSIDE, J., MACDOUGALL, R.H., HEISE, C., RANDLEV, B., GILLENWATER, A.M., BRUSO, P., KAYE, S.B., HONG, W.K., and KIRN, K.H. (2000). A controlled trial of intratumoral ONYX015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6, 879-885.
8. YOU, L., YANG, C.T., and JABLONS, D.M. (2000). ONYX015 works synergistically with chemotherapy in lung cancer cell lines and primary culture freshly made from lung cancer patients. Cancer Res. 60, 1009-1013.
9. NEMUNAITIS, J., GANLY, I., KHURI, F., ARSENEAU, J., KUHN, J., McCARTY, T., LANDERS, S., MAPLES, P., ROMEL, L., RANDLEV, B., REID, T., KAYE, S., and KIRN, D. (2000). Selective replication and oncolysis in p53 mutant tumors with ONYX015, an E1B55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 60, 6359-6366.
10. KRIN, D., MARTUZA, R.L., and ZWIEBEL, J. (2001). Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat. Med. 7, 781-787.
11. LIU, X.Y. (2001). A novel antitumor strategy - Targeting Gene-ViroTherapy for cancer. Chin. J. Cancer Biother. (Chinese) 8, 1.
12. WILEY, S.R., SCHOOLEY, K., SMOLAK, P.J., DIN, W.S., HUANG, C., NICHOLL, J.K., SUTHERLAND, G.R., DAVIS SMITH, T., RAUCH, S., SMITH, C.A., and GOODWIN, R.G. (1995). Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673-682.
13. WALCZAK, H., MILLER, R.E., ARIAIL, K., GLINIAK, B., GRIFFITH, T.S., KUBIN, M., CHIN, W., JONES, J., WOODWARD, A., LE, T., SMITH, C., SMOLAK, P., GOODWIN, R.G., RAUCH, C.T., SCHUH, J.C., and LYNCH, D.H. (1999). Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5, 157-163.
14. GRIFFITH, T.S., CHIN, W.A., JACKSON, G.C., LYNCH, D.H., and KUBIN, M.Z. (1999). Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 161, 2833-2840.
15. PITTI, R.M., MARSTERS, S.A., RUPPERT, S., DONAHUE, C.J., MOORE, A., and ASHKENAZI, A. (1996). Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271, 12687-12690.
16. PAN, G., NI, J., WEI, Y.F., YU, G., GENTZ, R., and DIXIT, V.M. (1997). An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277, 815-818.
17. SHERIDAN, J.P., MARSTERS, S.A., PITTI, R.M., GURNEY, A., SKUBATCH, M., BALDWIN, D., RAMAKRISHNAN, L., GRAY, C.L., BARKER, K., WOOD, W.I., GODDARD, A.D., GODOWSKI, P., and ASHKENAZI, A. (1997). Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277, 818-821.
18. WALCZAK, H., DEGLI-ESPOSTI, M.A., JOHNSON, R.S., SMOLAK, P.J., WAUGH, J.Y., BOIANI, N., TIMOUR, M.S., GERHART, M.J., SCHOOLEY, K.A., SMITH, C.A., GOODWIN, R.G., and RAUCH, C.T. (1997). TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16, 5386-5397.
19. DEGLI-ESPOSTI, M.A., DOUGALL, W.C., SMOLAK, P.J., WAUGH, J.Y., SMITH, C.A., and GOODWIN, R.G. (1997). The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7, 813-820.
20. EMERY, J.G., McDONNELL, P., BURKE, M.B., DEEN, K.C., LYN, S., SILVERMAN, C., DUL, E., APPELBAUM, E.R., EICHMAN, C., DIPRINZIO, R., DODDS, R.A., JAMES, I.E., ROSENBERG, M., LEE, J.C., and YOUNG, P.R. (1998). Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273, 14363-14367.
21. KEANE, M.M., ETTENBERG, S.A., NAU, M.M., RUSSELL, E.K., and LIPKOWITZ, S. (1999). Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 59, 734-741.
22. ASHKENAZI, A., PAI, R.C., FONG, S., LEUNG, S., LAWRENCE, D.A., MARSTERS, S.A., BLACKIE, C., CHANG, L., McMURTREY, A.E., HEBERT, A., DEFORGE, L., KOUMENIS, I.L., LEWIS, D., HARRIS, L., BUSSIERE, J., KOEPPEN, H., SHAHROKH, Z., and SCHWALL, R.H. (1999). Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155-162.
23. MIZUTANI, Y., NAKANISHI, H., YOSHIDA, O., FUKUSHIMA, M., BONAVIDA, B., and MIKI, T. (2002). Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur. J. Cancer 38, 167-176.
24. BONAVIDA, B., NG, C.P., JAZIREHI, A., SCHILLER, G., and MIZUTANI, Y. (1999). Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics. Int. J. Oncol. 15, 793-802.
25. NAGANE, M., HUANG, H.-J.S., and CAVENEE, W.K. (2001). The potential of TRAIL for cancer chemotherapy. Apoptosis 6, 191-197.
26. LEE, J.W., HAMPL, M., ALBERT, P., and FINE, H.A. (2002). Antitumor activity and prolonged expression from a TRAIL-expression adenoviral vector. Neoplasia 4, 312-323.
27. ZHANG, Z.L., ZOU, W.G., LUO, C.X., LI, B.H., QIAN, Q.J., and LIU, X.Y. (2003). An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res. 13, 481-489.
28. ICHIKAWA, K., LIU, W., ZHAO, L., WANG, Z., LIU, D., OHTSUKA, T., ZHANG, H., MOUNTZ, J.D., KOOPMAN, W.J., KIMBERLY, R.P., and ZHOU, T. (2001). Tumoricidal activity of a novel antihuman DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 7, 954-960.
29. JO, M., KIM, T.H., SEOL, D.W., ESPLEN, J.E., DORKO, K., BILLIAR, T.R., and STROM, S.C. (2000). Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 6, 564-567.
30. LAWRENCE, D., SHAHROKH, Z., MARSTERS, S., ACHILLES, K., SHIH, D., MOUNHO, B., HILLAN, K., TOTPAL, K., DEFORGE, L., SCHOW, P., HOOLEY, J., SHERWOOD, S., PAI, R., LEUNG, S., KHAN, L., GLINIAK, B., BUSSIERE, J., SMITH, C.A., STROM, S.S., KELLEY, S., FOX, J.A., THOMAS, D., and ASHKENAZI, A. (2001). Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 7, 383-384.
31. LIN, T., GU, J., ZHANG, L., HUANG, X., STEPHENS, L.C., CURLEY, S.A., and FANG, B. (2002). Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. Cancer Res. 62, 3620-3625.
32. LIN, T., HUANG, X., GU, J., ZHANG, L., ROTH, J.A., XIONG, M., CURLEY, S.A., YU, Y., HUNT, K.K., and FANG, B. (2002). Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene 21, 8020-8028.
33. KAGAWA, S., HE, C., GU, J., KOCH, P., RHA, S.J., ROTH, J.A., CURLEY, S.A., STEPHENS, L.C., and FANG, B. (2001). Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res. 61, 3330-3338.
34. SHISLER, J., DUERKSEN-HUGHES, P., HERMISTON, T.M., WOLD, W.S., and GOODING, L.R. (1996). Induction of susceptibility to tumor necrosis factor by E1A is dependent on binding to either p300 or p105-Rb and induction of DNA synthesis. J. Virol. 70, 68-77.
35. ROUTES, J.M., RYAN, S., CLASE, A., MIURA, T., KUHL, A., POTTER, T.A., and COOK, J.L. (2000). Adenovirus E1A oncogene expression in tumor cells enhances killing by TNF-related apoptosis-inducing ligand (TRAIL). J. Immunol. 165, 4522-4527.